Moderna-Merck Vaccine Cuts Recurrence And Spread of Melanoma, Raises New Treatment Hope
A major success in a new field of cancer treatment this week, as Moderna and Merck announced a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial. The vaccine was tested with Merck’s widely used immunotherapy drug Keytruda: Thousands of patients who Read more…






